Clinical Significance of PDCD4 in Melanoma by Subcellular Expression and in Tumor-Associated Immune Cells
Authors:
- Thuy T. TranTTThuy T. Tran
- Chetan K. RaneCRChetan K. Rane
- Christopher R. ZitoCZChristopher R. Zito
- Sarah A. WeissSWSarah A. Weiss
- Shlomit JesselSJShlomit Jessel
- Liliana LuccaLLLiliana Lucca
- Benjamin Y. LuBLBenjamin Y. Lu
- Victor O. OriaVOVictor O. Oria
- Adebowale AdeniranAAAdebowale Adeniran
- Veronica L. ChiangVCVeronica L. Chiang
- Sacit Bulent OmaySOSacit Bulent Omay
- David A. HaflerDHDavid A. Hafler
Open Access
Abstract
Little is known about the subcellular localization and function of programmed cell death 4 (PDCD4) in melanoma. Our past studies suggest PDCD4 interacts with Pleckstrin Homology Domain Containing A5 (PLEKHA5) to influence melanoma brain metastasis outcomes, as high intracranial PDCD4 expression leads to improved survival. We aimed to define the subcellular distribution of PDCD4 in melanoma and in the tumor microenvironment during neoplastic progression and its impact on clinical outcomes. We analyzed multiple tissue microarrays with well-annotated clinicopathological variables using quantitative immunofluorescence and evaluated single-cell RNA-sequencing on a brain metastasis sample to characterize PDCD4+ immune cell subsets. We demonstrate differences in PDCD4 expression during neoplastic progression, with high tumor and stromal PDCD4 levels associated with improved survival in primary melanomas and in intracranial metastases, but not in extracranial metastatic disease. While the expression of PDCD4 is well-documented on CD8+ T cells and natural killer cells, we show that it is also found on B cells and mast cells. PDCD4 expression in the tumor microenvironment is associated with increased immune cell infiltration. Further studies are needed to define the interaction of PDCD4 and PLEKHA5 and to evaluate the utility of this pathway as a therapeutic target in melanoma brain metastasis.Keywords
Funding Information
- National Cancer Institute (R01CA204002, K12CA215110, P50CA121974)
- National Institutes of Health (R01CA227472, R01CA216846, K12CA215119)
- American Cancer Society (130157-RSG-16-216-01-TBG)
- Yale SPORE in Lung Cancer Career Enhancement Program (2P50CA196530-06)
This publication has 61 references indexed in Scilit:
- Down-regulation of PDCD4 expression is an independent predictor of poor prognosis in human renal cell carcinoma patientsJournal of Cancer Research and Clinical Oncology, 2011
- MicroRNA miR-21 Regulates the Metastatic Behavior of B16 Melanoma CellsJournal of Biological Chemistry, 2011
- Quantitative expression of VEGF, VEGF-R1, VEGF-R2, and VEGF-R3 in melanoma tissue microarraysHuman Pathology, 2010
- Integrated Molecular and Clinical Analysis of AKT Activation in Metastatic MelanomaClinical Cancer Research, 2009
- Loss of Programmed cell death 4 (Pdcd4) associates with the progression of ovarian cancerMolecular Cancer, 2009
- The tumour suppressor Pdcd4: recent advances in the elucidation of function and regulationBiology of the Cell, 2009
- Expression of miR-21 and its targets (PTEN, PDCD4, TM1) in flat epithelial atypia of the breast in relation to ductal carcinoma in situ and invasive carcinomaBMC Cancer, 2009
- Loss of programmed cell death 4 expression marks adenoma‐carcinoma transition, correlates inversely with phosphorylated protein kinase B, and is an independent prognostic factor in resected colorectal cancerCancer, 2007
- S6K1- and ßTRCP-Mediated Degradation of PDCD4 Promotes Protein Translation and Cell GrowthScience, 2006
- Incidence Proportions of Brain Metastases in Patients Diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance SystemJournal of Clinical Oncology, 2004